Related Posts

• 
  Building a Roadmap to Biomarker Qualification: Challenges and Opportunities
• 
  Catalyzing The Critical Path Initiative: FDA’s Progress In Drug Development Activities
• 
  “Consortia Cross Talk,” on p. 12 of “BioCentury Innovations”
• 
  C-Path’s CEO, Martha A. Brumfield, featured on FasterCures blog
• 
  FDA releases Guidance for Drug Development Tool Qualification